NASDAQ NMS - GLOBAL MARKET · KRSA
-1.95% · -$0.6700 · Vol Not reported
After hours · updated 16:00:00 ET
Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc

Biotechnology
$33.65
Card
Relationship Map

Follow $KRSA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $KRSA by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Valuation absence reason unknown · Sentiment absence reason unknown
KRSA
Cyclerion Therapeutics Inc
Thu Oct 15 · session closed · Markets closed · resumes Fri 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

63/ 100
Veridion Score
Upper range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →or $250/yr
Cancel anytime · or Reserve · $79/moor $790/yr
Confidence: LOW · 4 of 6 factors measured · Thu Oct 15 · session closed · Markets closed · resumes Fri 9:30 ET
Share on X →
AI Analysis
Sovereign

Why is KRSA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and available price action.
About Cyclerion Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2026
Country
US

Korsana Biosciences Inc is a biopharmaceutical company developing therapeutics to treat neurodegenerative diseases beginning with Alzheimer's disease (AD. The company's flagship product candidate, KRSA-028, is an anti-amyloid beta antibody that combines the proprietary Therapeutic Targeting (THETA) platform with well-validated aspects from other anti-Ab products that have achieved regulatory approval or are in late-stage clinical trials.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$34.70
Day high
$35.15
Day low
$33.42
Previous close
$34.32
52W high
$44.66
-24.65% from high
52W low
$7.56
70% of range
Market cap
$1.6B
Beta
0.59
Shares out
45.5M
Avg volume
82.2K
VWAP
$34.32
Last session
Price history computed in-house
1W
+0.42%
1M
+4.89%
3M
+32.06%
1Y
+102.83%
YTD
+278.52%
SMA 50 $30.11 · above
SMA 200 $20.83 · above
52W position 70%

KRSA overview

Veridion Score
63
Registered · 2026-10-15
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KRSA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Public disclosures

Congress activity in KRSA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

KRSA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KRSA in this window.
Lobbying spend

KRSA lobbying filings, year to date.

Registered lobbying filings matched to Cyclerion Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KRSA in this window.
Analyst ratings
Sovereign unlock shows available analyst consensus for KRSA.
Veridion by email

Disclosure findings, methodology notes, and product updates when we have them. No fixed schedule yet. No advertising list resale.